Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?

Journal of Hepatology

Volumn 69, Issue 2, 2018, Pages 548-550

  Gauci, Marie Léa ^a,b   Baroudjian, Barouyr ^a,b   Zeboulon, Charlotte ^a,b   Pages, Cécile ^a,b   Poté, Nicolas ^c,d   Roux, Olivier ^c   Bouattour, Mohamed ^e   Lebbé, Céleste ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c BEAUJON HOSPITAL   (France)

^d CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Anti CTLA4; Anti PD 1; Immune checkpoint inhibitors; Immune related adverse events; Immune related hepatitis

Indexed keywords

AMINOTRANSFERASE; ATEZOLIZUMAB; AVELUMAB; BILIRUBIN; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; URSODEOXYCHOLIC ACID; CORTICOSTEROID;

ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER IMMUNOTHERAPY; CORTICOSTEROID THERAPY; FATTY LIVER; HEPATITIS; HUMAN; IMMUNE SYSTEM; LETTER; LIVER BIOPSY; LIVER TOXICITY; MELANOMA; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; IMMUNOTHERAPY; NEOPLASM;

ADRENAL CORTEX HORMONES; HEPATITIS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 85049560618     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.03.034     Document Type: Letter

References (10)

1. De Martin, E., Michot, J.-M., Papouin, B., Champiat, S., Mateus, C., Lambotte, O., et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 68 (2018), 1181–1190.
2. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
3. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
4. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
5. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab vs. ipilimumab in advanced melanoma. N Engl J Med, 372, 2015, 10.1056/NEJMoa1503093.
6. Zhang, X., Ran, Y., Wang, K., Zhu, Y., Li, J., Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: A meta-analysis. Drug Des Devel Ther 10 (2016), 3153–3161.
7. Bernardo, S.G., Moskalenko, M., Pan, M., Shah, S., Sidhu, H.K., Sicular, S., et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res 23 (2013), 47–54.
8. Haanen, J.B.A.G., Carbonnel, F., Robert, C., Kerr, K.M., Peters, S., Larkin, J., et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28 (2017), iv119–iv142.
9. Puzanov, I., Diab, A., Abdallah, K., Iii, C.O.B., Brogdon, C., Dadu, R., et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immuno Ther Cancer, 2017, 1–28.
10. Information IS, Full US, Information P, Information IS. Immune-mediated adverse reactions management guide OPDIVO® is approved in 8 tumor types n.d.:62–5.